Diagnostics antibodies and antigens for gastric disease

Gastric disorders are the most common disease leads to the death. Most death of gastric disease is mostly due the diagnosis at late-stage. The diagnosis of Gastric disease at early-stage is delayed due to the lack symptoms and effective Diagnostics technique. The traditional technology, including endoscopic examination and gastroscopic biopsy are invasive to screen large population. Hence, biomarkers such as pepsinogen I, Pepsinogen II, Gastrin 17, trefoil factor 1, Gastrin and so on have been developed to detect the gastric diseases at an early stage for large population to significantly reduce the death caused by gastric cancer. However, the detection of these marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.

Classification: PG I PG II G17 TFF1 G100